Omeros | OMER - Operating Profit


Omeros reported $-35.41M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Adma Biologics USD 52.44M 2.15M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
MacroGenics USD -13.85M 19.59M Jun/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 662M 5M Sep/2026
Rockwell Medical USD 515K 1.84M Jun/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
United Therapeutics USD 241.3M 89.5M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026